Figure 4.

Prevention of gouty arthritis recurrence by compound tufuling oral-liquid. (A) PPS analysis (Pearson χ² test): from baseline to end of week 6, 32.14% and 48.28% in treatment and control group, respectively, P = 0.04; from end of week 6 to end of week 12, 22.02% and 50.88% in treatment and control group, respectively, P < 0.001; and from baseline to end of week 12, 38.53% and 63.16%in treatment and control group, P = 0.003. (B) ITT analysis (Pearson χ² test): from baseline to end of week 6, 30.77% and 44.44% in treatment and control group, respectively, P = 0.062; from end of week 6 to end of week 12, 21.93% and 50.88% in treatment and control group, respectively, P < 0.001; and from baseline to end of week 12, 39.50% and 63.16% in treatment and control group, respectively, P = 0.003. ITT = intention-to-treat, PPS = per-protocol population set.